KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Amortizatization of Intangibles (2016 - 2025)

Historic Amortizatization of Intangibles for Inovio Pharmaceuticals (INO) over the last 17 years, with Q3 2025 value amounting to $399458.0.

  • Inovio Pharmaceuticals' Amortizatization of Intangibles rose 1237.97% to $399458.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 4765.2%. This contributed to the annual value of $1.7 million for FY2024, which is 6392.5% down from last year.
  • Inovio Pharmaceuticals' Amortizatization of Intangibles amounted to $399458.0 in Q3 2025, which was up 1237.97% from $385519.0 recorded in Q2 2025.
  • Inovio Pharmaceuticals' Amortizatization of Intangibles' 5-year high stood at $1.2 million during Q2 2023, with a 5-year trough of -$482301.0 in Q4 2021.
  • Moreover, its 5-year median value for Amortizatization of Intangibles was $355454.0 (2024), whereas its average is $447693.5.
  • As far as peak fluctuations go, Inovio Pharmaceuticals' Amortizatization of Intangibles plummeted by 17638.57% in 2021, and later skyrocketed by 93276.17% in 2023.
  • Quarter analysis of 5 years shows Inovio Pharmaceuticals' Amortizatization of Intangibles stood at -$482301.0 in 2021, then soared by 172.33% to $348870.0 in 2022, then soared by 199.36% to $1.0 million in 2023, then plummeted by 82.74% to $180251.0 in 2024, then surged by 121.61% to $399458.0 in 2025.
  • Its Amortizatization of Intangibles was $399458.0 in Q3 2025, compared to $385519.0 in Q2 2025 and $372083.0 in Q1 2025.